News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The drug is priced at Rs 2000 for a course of 40 tablets
The transaction is expected to close in the first quarter of 2022
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
He has over 22 years of experience in pharmaceutical sales & business development
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Subscribe To Our Newsletter & Stay Updated
